NovaBay Pharmaceuticals Inc (NBY)
0.1112
-0.03
(-19.99%)
USD |
NYAM |
Mar 27, 16:00
0.111
0.00 (0.00%)
After-Hours: 05:13
NovaBay Pharmaceuticals SG&A Expense (Quarterly): 2.943M for Sept. 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | 2.943M |
June 30, 2023 | 3.634M |
March 31, 2023 | 3.644M |
December 31, 2022 | 4.378M |
September 30, 2022 | 2.791M |
June 30, 2022 | 3.95M |
March 31, 2022 | 4.168M |
December 31, 2021 | 4.864M |
September 30, 2021 | 3.832M |
June 30, 2021 | 3.357M |
March 31, 2021 | 2.867M |
December 31, 2020 | 2.797M |
September 30, 2020 | 3.571M |
June 30, 2020 | 2.90M |
March 31, 2020 | 2.837M |
December 31, 2019 | 3.331M |
September 30, 2019 | 2.877M |
June 30, 2019 | 2.733M |
March 31, 2019 | 5.136M |
December 31, 2018 | 4.688M |
September 30, 2018 | 4.574M |
June 30, 2018 | 4.337M |
March 31, 2018 | 5.018M |
December 31, 2017 | 4.801M |
September 30, 2017 | 5.607M |
Date | Value |
---|---|
June 30, 2017 | 5.111M |
March 31, 2017 | 6.828M |
December 31, 2016 | 5.143M |
September 30, 2016 | 4.929M |
June 30, 2016 | 4.146M |
March 31, 2016 | 4.826M |
December 31, 2015 | 6.088M |
September 30, 2015 | 4.716M |
June 30, 2015 | 4.257M |
March 31, 2015 | 3.468M |
December 31, 2014 | 2.716M |
September 30, 2014 | 1.911M |
June 30, 2014 | 1.653M |
March 31, 2014 | 1.708M |
December 31, 2013 | 1.259M |
September 30, 2013 | 1.525M |
June 30, 2013 | 2.045M |
March 31, 2013 | 1.56M |
December 31, 2012 | 1.828M |
September 30, 2012 | 1.234M |
June 30, 2012 | 1.368M |
March 31, 2012 | 1.541M |
December 31, 2011 | 1.499M |
September 30, 2011 | 1.097M |
June 30, 2011 | 1.318M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.733M
Minimum
Jun 2019
5.136M
Maximum
Mar 2019
3.506M
Average
3.357M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Eyenovia Inc | 3.402M |
Sonoma Pharmaceuticals Inc | 1.703M |
Palatin Technologies Inc | 3.033M |
iBio Inc | 2.961M |
Theriva Biologics Inc | 0.212M |